Ranbaxy Laboratories
May 29, 2012 at 14:42 | Source: CNBC-TV18
May 29, 2012 at 12:30 | Source: Moneycontrol.com
May 28, 2012 at 16:46 | Source: Reuters
May 28, 2012 at 14:41 | Source: Moneycontrol.com
May 28, 2012 at 11:26 | Source: Moneycontrol.com
News across the web »
May 29, 2012 at 19:22 | Source: Business Standard
May 29, 2012 at 17:16 | Source: Economic Times
Ranbaxy gets US nod for acne treatmentCompany expects a US launch in the fourth quarter of this year
May 28, 2012 at 21:02 | Source: Business Standard
May 28, 2012 at 21:02 | Source: India Infoline
May 28, 2012 at 11:11 | Source: Economic Times
Interact & exchange stock tips & market info »
Related News »
MUMBAI (Reuters) - Ranbaxy Laboratories (RANB.NS) has received U.S. approval for acne treatment drug Absorica and expects a U.S. launch in the fourth quarter of this year. The product was jointly developed by Canadian group Cipher ...
May 28, 2012 at 11:06 | Source: Reuters India
New Delhi: Drug firm Ranbaxy Laboratories on Monday said it has received approval from the US health regulator to launch Absorica, a patented acne treatment drug developed by Canadian firm Cipher Pharmaceuticals Inc, in the American market.
May 28, 2012 at 21:36 | Source: zeenews.india.com
Sudarshan Sukhani, s2analytics.com feels that one can buy Ranbaxy Laboratories and avoid OMCs stocks. Sukhani told CNBC-TV18, “ Ranbaxy Laboratories is now in its own bull market. It is outperforming and likely to outperform the Nifty.
May 29, 2012 at 11:27 | Source: MoneyControl.com
PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica™, a ...
May 29, 2012 at 14:04 | Source: Yahoo Finance
BANGALORE -(Dow Jones)- Ranbaxy Laboratories Ltd. (500359.BY) said Monday Canadian partner Cipher Pharmaceuticals Ltd. (DND.T) has received U.S. regulatory approval to make and sell a patented formulation of the acne medication Absorica.
May 29, 2012 at 10:58 | Source: NASDAQ
Tokyo, May 25 (PTI) Drug major Ranbaxy Laboratories today said it has hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India as part of a consent decree signed with the USFDA to revoke ban imposed by the ...
May 25, 2012 at 09:30 | Source: MSN India
"We look forward to working closely with our partner, Ranbaxy Laboratories Inc., in preparation for the upcoming U.S. launch of the product through its dermatology sales force." "We are thrilled to make Absorica available as a valuable option for the ...
May 28, 2012 at 11:28 | Source: Stockhouse
Genericsmakers are preparing to flood the market with copycat Lipitor, now that Ranbaxy Laboratories' exclusivity period is expiring. But Teva Pharmaceutical Industries ($TEVA) won't be joining the throng. The Israeli company is opting out.
May 29, 2012 at 15:23 | Source: FiercePharma
According to a report from the "Economic Times of India", Teva has instead decided that it will help Indian companies Ranbaxy Laboratories and Dr. Reddy's Laboratories capture a larger market share of the drug in the US. Teva Americas CEO William Marth ...
May 29, 2012 at 06:26 | Source: Globes - Israel Business Arena
Ranbaxy Laboratories received FDA approval to market Cipher Pharmaceuticals' acne treatment Absorica. "Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy's specialized ...
May 29, 2012 at 14:33 | Source: SmartBrief